Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
TruScreen Group Ltd. ( (AU:TRU) ) has shared an announcement.
TruScreen Group Limited has gained its first clinical validation for the use of its TruScreen Ultra device in pregnant women, following the publication of a 2,000-patient study in leading Chinese medical journal Family Doctor. Conducted at Guilin People’s Hospital and comparing TruScreen with the ThinPrep Cytologic Test (TCT), the study found similar diagnostic performance but better tolerance and lower post-procedure bleeding with TruScreen, highlighting its advantages as a non-invasive, real-time screening tool that avoids sampling-related limitations. The findings, which position TruScreen as a simple, safe, and well-tolerated initial and supplementary screening method for cervical lesions in pregnancy, could support wider clinical adoption in China, the company’s largest market, and enhance its competitive standing in cervical cancer screening, particularly among pregnant patients where safety and compliance are critical.
More about TruScreen Group Ltd.
TruScreen Group Limited develops and markets AI-enabled, real-time, non-invasive cervical cancer screening devices, with a significant market presence in China, where it targets a large female screening population through both clinical and consumer-facing medical channels.
Average Trading Volume: 208,231
Technical Sentiment Signal: Hold
Current Market Cap: A$10.86M
For an in-depth examination of TRU stock, go to TipRanks’ Overview page.